156 results
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required
8-K
EX-4.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
8-K
EX-10.1
wylfofj
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
UPLOAD
fwoualmp
29 Jan 24
Letter from SEC
12:00am
8-K
EX-4.2
k4xafge1 792la4o9
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
65ono6wt
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.2
dpkxu7o
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
fg671gdupxmzym84
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.2
o64dob 7f
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
mcwjzh q08or4cvfev
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm